Male Fertility Gene Atlas

CRU Male Germ Cells

About Publications Search Walk Through

Table 1. Baseline characteristics of the patient cohort.

PORTELA, Joana, et al. Development and disease-dependent dynamics of spermatogonial subpopulations in human testicular tissues. Journal of clinical medicine, 2020, 9. Jg., Nr. 1, S. 224.

Publication: https://doi.org/10.3390/jcm9010224

Description

According to diagnosis, treatment received and occurrence of any testicular pathology, patients were divided into two groups: NT: untreated cancer patients without any preexisting (congenital) risk factors for impaired testicular function; AT: patients with potentially affected tissues by disease or treatment. The average age of the patients in NT and AT group is not significantly different (9.1 and 9.5 years, respectively).

* Patients with low spermatogonial counts and a patient with germ cell neoplasia in situ (AT21) were excluded from further analysis. Testicular volumes were determined by palpation using a Prader orchidometer and additionally confirmed by ultrasonography. # Indicates one patient for whom testicular volume was only determined by Prader orchidometer.

Disclaimer

The publication Development and Disease-Dependent Dynamics of Spermatogonial Subpopulations in Human Testicular Tissues by Joana M. D. Portela, Laura Heckmann, Joachim Wistuba, Andrea Sansone, Ans M. M. van Pelt, Sabine Kliesch, Stefan Schlatt and Nina Neuhaus is published under an open access license: https://creativecommons.org/licenses/by/4.0/. Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Curation by the MFGA team

Pie chart of selected column

Table

PatientNumber Diagnosis(treatmentBeforeTestisBiopsy) Group Age(years) TestisVolume(ml)
NT1 Ependymoma NT 2.5 1.5
NT2 * Acute myeloid leukemia NT 3 0.33
NT3 Hodgkins lymphoma NT 5 1
NT4 Hodgkins lymphoma NT 6 1
NT5 Rhabdomyosarcoma NT 7 0.83
NT6 Ewing sarcoma NT 8 0.40
NT7 Intracranial germ cell tumor NT 9 1.3
NT8 Rhabdomyosarcoma NT 10.5 1.8
NT9 Hodgkins lymphoma NT 11 1
NT10 Osteosarcoma NT 11 2
NT11 Hodgkins lymphoma NT 13 1
NT12# Sarcoma NT 14 8
NT13 Lymphoma NT 14 19
NT14 Non-Hodgkins lymphoma NT 14 9
AT1 Immunodeficiency (chemotherapy) AT 0.42
AT2 Thalassemia AT 2 0.3
AT3 Testicular tumor; pubertas praecox AT 3 8
AT4 Immunodeficiency AT 4 0.4
AT5 Leukemia (allogeneic bone marrow transplantation) AT 6
AT6 Sickle cell disease (hydroxyurea) AT 6 1
AT7 Myelodysplastic syndrome AT 7 1
AT8 * Sickle cell disease; cryptorchid testes AT 7 1
AT9 Sickle cell disease (hydroxyurea) AT 8 0.3
AT10 Myelodysplastic syndrome AT 9 1
AT11 Thalassemia major AT 10 1
AT12 Hodgkins lymphoma; cryptorchid testes AT 10 1
AT13 Sickle cell disease (hydroxyurea) AT 10 2
AT14 Myelodysplastic syndrome AT 12 1.4
AT15 * Cryptorchid testes; hypogonadism AT 12 -
AT16 Thalassemia major AT 12 1
AT17 Leukemia (chemotherapy) AT 13 8
AT18 * Cryptorchid testes AT 14 6
AT19 Lymphoma (chemotherapy) AT 15 6
AT20 Leukemia; cryptorchid testes (chemotherapies) AT 16 5
AT21 * Testicular tumor; cryptorchid testes AT 16 3
AT22 Cryptorchid testes AT 17 3